Press

Wellbeing Digital and Subsidiary KGK Science Applauds the Government of Alberta’s Move to Regulate the Use of Psychedelics

Oct 14 • 3 min read

Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, together with its wholly owned subsidiary KGK Sciences Inc. (‘KGK’), applauds the efforts on the part of the Alberta…

Love Pharma – Johns Hopkins University Psilocybin Trial Advances Toward Launch in 2022

Oct 13 • 3 min read

LOVE Pharma Co.(CSE:LUV | FSE:G1Q0), the Company is pleased to provide the following update on the advancement of the previously announced trial focused upon clinical applications for psilocybin assisted therapy for addiction to be conducted at Johns Hopkins. “LOVE is actively working to identify and assess biotechnology and pharmaceutical solutions to address addiction, with intent…

PSYC’s Spotlight Media Highlights Revenue Growth and Other Operational Achievements Met in Q3

Oct 13 • 5 min read

PSYC Corporation (OTCPink: PSYC), a media leader focused on the emerging psychedelic and cannabis sectors, is pleased to report a 42% increase in revenue from 2022 Q2 to Q3 and other operational highlights through its wholly owned subsidiary Spotlight Media Corp. (“SMC”). The Company contends that the following details can be viewed as operational highlights that were achieved by…

IntelGenx Says Atai Life Sciences Collaboration Leads to Start of First-in-Human Clinical Study of Oral Thin Film Psychedelic Drug Candidate

Oct 13 • 1 min read

IntelGenx Corp. (IGX.TO) on Thursday provided an update on its collaboration with its strategic partner, Atai Life Sciences (atai) for the development of novel formulations of pharmaceutical-grade psychedelics based on IntelGenx’s polymeric film technologies. Under the first of two current feasibility agreements between the companies, IntelGenx conducted pre-development, formulation development work and clinical supply manufacturing…

PharmAla appoints Dr. Leah Mayo to Scientific Advisory Board

Oct 13 • 3 min read

PharmAla Biotech (CSE: MDMA) is excited to welcome Dr. Leah Mayo to the company’s Scientific Advisory Board. Dr. Mayo recently took up the role of Parker Chair in Psychedelics Research at the Department of Psychiatry, the Hotchkiss Brain Institute and the Mathison Centre for Mental Health Research and Education at the University Calgary. Prior to her appointment,…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436